Servier has announced the completion of its acquisition of Day One Biopharmaceuticals, which is valued at roughly $2.5 billion. It represents a key milestone for Servier in its oncology program development, especially in rare tumors and pediatrics. Through this acquisition, OJEMDA™ (tovorafenib), the first FDA-approved drug for treating pediatric low-grade glioma, will be brought to Servier along with an exciting portfolio of clinical assets that address rare and high unmet need cancers. Day One’s portfolio, including therapies such as emiltatug ledadotin and DAY301, further strengthens Servier’s pipeline across multiple development stages.
Also Read: LabConnect Unveils SampleGISTICS® 2.0 to Digitize Sample
“This acquisition represents a significant step forward for Servier as part of our 2030 ambition to strengthen our position in rare cancers, and more specifically in pediatric low-grade glioma,” said Olivier Laureau, President of Servier. Servier wants to speed up innovation. This integration will help them use scientific expertise. They aim to provide targeted therapies. This improves outcomes for patients with life-threatening conditions.
